$VTEX

Gomide de Faria Mariano sold $19K of VTEX (indirect holdings)

Gomide de Faria Mariano (Chief Executive Officer) sold 4,808 indirectly-held shares of VTEX (VTEX) at $4.03 on 2026-10-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gomide de Faria Mariano
Published Oct 27, 2026, 3:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 3:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VTEX
Neutral
high confidence
Mentioned
$VTEX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VTEXNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

Routine insider sell with limited trading relevance.

03

What to watch

Potential tax planning or liquidity needs unrelated to company performance.

Relevance 2/10Novelty 2/10Timing: filing day

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$VTEXNeutralHigh confidence
Context

CEO sold 4,808 shares for $19,376 via a 10b5-1 plan, reducing his stake to 899,505 shares.

Expected impact

likely slight downward pressure as market prices in the insider sale

Evidence & confidence

The transaction size is modest ($19k) and disclosed via a Form 4, indicating a routine reduction of holdings rather than a material shift.

Market effects

Minimal impact on e‑commerce sector; insider sales are routine.

No broader regional effect.

Limited to VTEX shareholders.

Counterpoint

The sale could be a signal of upcoming negative news, but size is too small to infer.

Key entities

  • Gomide de Faria Mariano

    Chief Executive Officer of VTEX

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VTEXMed

VTEX (VTEX) Just Turned A Profit Corner, But Growth Is Slowing

VTEX (NYSE:VTEX) reported Q2 2026 results showing improved profitability with non-GAAP income from operations up 62.4% YoY to $13.8M, and free cash flow up 79.1% to $12.7M. However, revenue growth slowed to 1.3% YoY on an FX-neutral basis, with management expecting flat growth for Q3. The company repurchased 6.2M shares for $23.2M during the quarter.

$VTEXMedAI 8/10

VTEX (VTEX) Q2 2026 Earnings Call Transcript

VTEX reported Q2 2026 results in an earnings call. GMV was $5.7B, up 7% FX-neutral. Subscription revenue was $63.8M, up 1.3% FX-neutral. Non-GAAP operating income rose 62% to $13.8M, with a 21.4% margin. Free cash flow was $12.7M, up 79%. Q3 guidance calls for flat FX-neutral subscription growth.

$VTEXMedAI 8/10

VTEX Q2 Earnings Call Highlights

VTEX (NYSE:VTEX) reported Q2 margin and cash flow improvement and guided for Q3 and full-year low-single-digit FX-neutral subscription revenue growth and low-20% non-GAAP operating and free cash flow margins. Q2 non-GAAP subscription gross margin rose to 81.8%. Free cash flow rose 79% to $12.7M. VTEX repurchased 6.2M shares at $3.76.

$VTEXMed

VTEX (VTEX): Financial results for Q2 2026

VTEX (VTEX) furnished an SEC Form 6-K — earnings release. VTEX Reports Second Quarter 2026 Financial Results Subscription revenue grew 11.4% (+1.3% FXN), with GMV up 17.8% (+7.0% FXN) Non-GAAP income from operations increased 62.4% to US$13.8 million, reaching a 21.4% margin Free cash flow increased 79.1% to US$12.7 million, reaching a